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giant cell tumor of bone treated with denosumab
Michiyuki Hakozaki1*, Takahiro Tajino1, Hitoshi Yamada1, Osamu Hasegawa2, Kazuhiro Tasaki3,
Kazuo Watanabe4 and Shinichi Konno1Abstract: We describe a case of giant cell tumor of the proximal tibia with skip bone metastases of the ipsilateral
femur in a 20-year-old man. After the neoadjuvant treatment with denosumab, plain radiographs and computed
tomography showed marked osteosclerosis and sclerotic rim formation, and 18F-FDG PET/CT showed a decreased
standardized uptake value, whereas magnetic resonance imaging showed diffuse enhancement of the tumor, nearly
the same findings as those at pretreatment. Pathological findings of the surgical specimen after the denosumab
treatment showed benign fibrous histiocytoma-like features with complete disappearance of both mononuclear
stromal cells and multinuclear osteoclast-like giant cells.
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Giant cell tumor of bone (GCTB) is a rare, benign pri-
mary bone tumor that commonly occurs in young
adults. It accounts for approximately 5% of all primary
bone tumors and approximately 20% of all benign bone
tumors [1-5]. Though categorized as a benign skeletal
tumor, GCTB is also known for its locally aggressive be-
havior and high recurrence rates; 15%–50% after usual
curettage only, and 2.3%–20% after curettage with adju-
vant treatment (i.e., further debridement with a high-
speed burr, cryotherapy with liquid nitrogen, chemical
debridement with phenol, or bone cementing) [1,2,4,5].
To improve GCTB’s aggressive course, therefore, new
developments in therapy have been sought.
Denosumab, the novel monoclonal antibody against
receptor activator of nuclear factor-κB (RANK) ligand
(RANKL), has recently been used to treat patients with
GCTB. Although excellent efficacy of denosumab for
cases of advanced or unresectable GCTB has been re-
ported [5-9], the radiological and histopathological find-
ings of GCTB after the denosumab treatment were not* Correspondence: paco@fmu.ac.jp
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unless otherwise stated.described in detail. We describe herein a case of GCTB
of the proximal tibia with skip bone metastases, focusing
on the radiological and histopathological characteristics
observed before and after the preoperative treatment
with denosumab.
A previously healthy 20-year-old man with a 2-year
history of pain in the left proximal lower leg sprained
his left knee. After a radiological analysis at the primary
hospital, he was referred to our hospital. On admission,
the patient noted the pain around his left tibial tubercle
both on weight-bearing and at rest. Tenderness and local
warmth were observed on the proximal lower leg, and a
subcutaneous soft tissue mass was palpable through a
defect of cortical bone located just to the outer side of
the tibial tubercle. His standard laboratory data showed
no abnormalities. Plain radiographs revealed an osteolytic
lesion with a soap bubble-like multilocular appearance
and thinned cortical bone in the epiphysis of the left prox-
imal tibia (Figure 1A,B). Focal cortical expansion and a
partial cortical defect were seen.
Magnetic resonance imaging (MRI) revealed an intraoss-
eous tumor in the left proximal tibia, measuring 9.8 × 6.4 ×
5.8 cm in size and displaying iso-intensity to the sur-
rounding muscle on T1-weighted imaging (Figure 1C), het-
erogeneous high intensity on T2-weighted fat-suppressional Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Pre-treatment radiological analyses of the left knee of the patient. Plain radiographs show a soap-bubbly osteolytic lesion with
thinned cortical bone in the epiphysis of the proximal tibia (A, B) and small osteolytic lesions with a nonsclerotic margin in the metaphysis of the
distal femur (arrow). MRI shows a proximal tibial tumor displaying iso-intensity to the surrounding muscle on T1-weighted imaging (coronal view)
(C), heterogeneous high intensity on T2-weighted fat-suppression imaging (axial view) (D), and diffuse enhancement on gadolinium-enhanced
T1-weighted fat-suppression imaging (coronal view) (E). Enhancement of surrounding soft tissue which indicates an occult pathological fracture is
also observed. Sagittal MRI of the distal tibia shows small lesions (arrows) displaying nearly the same patterns as the tibial tumor; iso-intensity to
the surrounding muscle on T1-weighted imaging (F), high intensity on T2-weighted imaging (G), and diffuse enhancement on gadolinium-enhanced
T1-weighted fat-suppression imaging (H). 18F-FDG PET/CT revealed the proximal tibial tumor showing marked bone destruction (I) with increased SUV
uptake (SUVmax: 9.6) (J) and the distal femoral lesions with slightly increased SUV uptake (SUVmax: 0.7) (arrow) (K).
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gadolinium-enhanced T1-weighted fat-suppression
imaging (Figure 1E). Positron emission tomography with
2-deoxy-2-[fluorine-18]fluoro- D-glucose integrated with
computed tomography (18F-FDG PET/CT) showed bone
destruction of both cortical and cancellous bone without
sclerotic rim (Figure 1I), and an increased standardized
uptake value (SUV) on the proximal tibial tumor (SUV-
max: 9.6) (Figure 1J).
18F-FDG PET/CT also detected two small nodular
lesions in the distal metaphysis of the left femur (SUV-
max: 0.7 and 0.4) (Figure 1K) and no other distant
lesion. Plain radiographs (Figure 1A) and MRI of the
left distal femur revealed small osteolytic lesions,
which showed the same patterns in MRI as the tibial
tumor (Figure 1F-H). For the correct diagnosis, we
decided to make a histopathological diagnosis via an
incisional biopsy of the tibial tumor. The tumor sample
was extracted via the cortical defect.
Grossly, the tumor was soft, friable, and mixed dark
red-brown/yellow tissue which was thought to be com-
patible with GCTB. Microscopic findings showed a
diffuse proliferation of uniform, mononuclear, acido-
phil cells with oval or short-spindle-shaped nuclei and
ill-defined cytoplasm (stromal cells) and osteoclast-like
multinuclear giant cells with the similar nuclei as the
stromal cells (Figure 2). The mitotic rate was 3/20
high-power field, and atypical mitosis was absent. We
diagnosed the tumor as GCTB based on the histo-
pathological findings.Figure 2 Histological section of the biopsy specimen (pre-treatment).
multinuclear giant cells, i.e., typical microscopic findings of GCTB, can be seenAlthough we did not diagnose the femoral tumor
pathologically, we judged the femoral tumors as skip
metastatic tumors from the primary GCTB of the
proximal tibia, based mainly on the radiological find-
ings. We decided to treat this patient with denosumab.
After dental treatment to prevent osteonecrosis of the
jaw, the patient received a hypodermic injection of
120 mg of denosumab at 4-week intervals a total of six
times, along with oral calcium lactate (3 g/day) and
eldecalcitol (0.75 μg/day). During this treatment, no
adverse side effect occurred other than slight hypo-
calcemia (grade 1, Common Terminology Criteria for
Adverse Events [CTCAE] Version 4 [10]).
The pain around the patient’s left knee disappeared
immediately after the first administration of denosumab
and he could walk without cane (full-weight bearing).
Follow-up plain radiographs were taken every 4 weeks
and they showed the progressive osteosclerosis. Six
months after the initial denosumab treatment, plain
radiographs showed marked osteosclerosis and sclerotic
rim formation on both the proximal tibial tumor and the
distal femoral tumors (Figure 3A,B). The cortical defect of
the left proximal tibia disappeared. 18F-FDG PET/CT
showed both marginal/intralesional osteosclerosis and
osteogenesis (Figure 3F) and a marked decrease in the
SUV (SUVmax of the tibial tumor: 4.8, SUVmax of the
femoral tumors: 1.3) (Figure 3G). Conversely, MRI
showed iso-intensity to the surrounding muscle on
T1-weighted imaging (Figure 3C) and diffuse enhancement
on gadolinium-enhanced T1-weighted fat-suppressionThe diffuse proliferation of mononuclear stromal cells and osteoclast-like
(hematoxylin-eosin stain; A, ×100; B, ×200).
Figure 3 Post-treatment radiological analyses of the left knee. Plain radiographs show marked osteosclerosis and sclerotic rim formation on
both the proximal tibial tumor (A, B) and distal femoral tumors. MRI shows a tumor displaying iso-intensity to the surrounding muscle on T1-weighted
imaging (coronal view) (C), heterogeneous high intensity (but lower than at pretreatment) on T2-weighted imaging (axial view) (D), and
diffuse enhancement on gadolinium-enhanced T1-weighted fat-suppression imaging (coronal view) (E). 18F-FDG PET/CT revealed the
marginal/intralesional osteosclerosis of the proximal tibial tumor (F) with markedly decreased SUV uptake (SUVmax: 4.8 in the tibial tumor) (G).
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as those at pretreatment, and conversely high intensity
(but lower than pretreatment) on T2-weighted imaging
(Figure 3D). At seven months after the initial medical
examination, we performed surgery for the proximal
tibial tumor: curettage and further debridement with a
high-speed burr, cryotherapy with liquid nitrogen, graft-
ing of beta-tricalcium phosphate, and internal fixation
with titanium screws.
On gross examination during the operation, we ob-
served thickened cortical bone, peripheral trabecular
bone, and internal wall. The tumor was a white, elastic-
hard mass which was completely different from the
pretreated tumor. Microscopically, the curetted tumor
showed diffuse proliferation of short-spindle-shaped cells
arranged in a storiform pattern, a benign fibrous histio-
cytoma (BFH)-like feature (Figure 4), which may be par-
tially observed in some cases of GCTB [11]. While nests
of foam cells were scattered, neither stromal cells nor
giant cells were observed. The spindle-shaped cells did
not have atypical nuclei, and mitotic figures were absent.
Partial reactive bone formation was observed. We histo-
pathologically diagnosed the surgical specimen as a
post-therapeutic BFH-like lesion after the denosumab
treatment for GCTB.
From the post-therapeutic findings of the proximal
tibial tumor, there seemed to be BFH-like tissue with no
viable stromal cells or giant cells in the femoral tumors.
Thus, we decided not to perform surgical treatment on
the femoral tumors and to continue radiological obser-
vation only.
The patient’s postoperative course was uneventful, and a
plain radiograph taken six months after the operation
revealed bone union and consolidation without findings of
local recurrence. The radiological findings of the femoral
tumors showed no remarkable changes after the operation.
GCTB is histologically characterized by the diffuse
growth of RANKL-positive mononuclear stromal cells
and RANK-positive osteoclast-like giant cells [12]. Since
RANKL is a key mediator of osteoclast activation, theFigure 4 Post-treatment histological section of the surgical specimen
storiform pattern (mimicking benign fibrous histiocytoma) involving bone form
cells and osteoclast-like giant cells have disappeared. (hematoxylin-eosin stainRANK-RANKL interaction in GCTB is thought to par-
ticipate in the growth of the tumor cells, possibly as a
result of the production of growth factors by osteoclast-
like giant cells through a paracrine loop [8,13]. The
inactivation of osteoclasts by denosumab, a human
monoclonal antibody that specifically inhibits RANKL,
disturbs the bone destruction in patients with osteo-
porosis [14] and in malignant bone tumors, such as
multiple myelomas [15] and metastatic bone tumors [16].
In light of its mechanism of action, clinical efficacy of
denosumab for GCTB had been expected.
Since the first report of the efficacy of denosumab for
GCTB by Thomas and colleagues in 2010 [6], several
studies about this new treatment for GCTB have been
published. In these reports, the efficacy of denosumab
was evaluated mainly by pathological findings; i.e., the
disappearance or decreased number of stromal cells and
giant cells, apoptosis or necrosis of tumor cells, fibrosis or
increased fibro-osseous tissue, and osteogenesis [7-9,12].
However, these reports did not provide radiological
findings, especially in a comparative analysis with radio-
logical and pathological findings.
In the present study, we evaluated the efficacy of denosu-
mab for GCTB both radiologically and pathologically. Our
comparative observation demonstrated that the marked
osteosclerosis and sclerotic rim formation shown by plain
radiographs and CT reflect the devitalization of giant cells
and reactive bone formation, and we found that the
decreased SUVmax shown by 18F-FDG PET/CT relates
to the disappearance of tumor cells, mononuclear stro-
mal cells and giant cells.
Conversely, the findings obtained by enhanced MRI
pre- and post-treatment were similar, presenting a
diffuse proliferation of a BFH-like lesion which was
enhanced by gadolinium. Enhanced MRI thus seems to
be less useful than plain radiographs or 18F-FDG PET/
CT for evaluating the efficacy of denosumab treatment
for GCTB. However, on plain MRI, T1-weighted im-
aging was not changed after the denosumab treatment,
whereas the intensity of the post-treated tumor on T2-. The diffuse proliferation of short-spindle-shaped cells arranged in a
ation is shown. Clusters of foam cells are also seen. Both the stromal
; A, ×100; B, ×200).
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ment) in contrast to the circumferential muscle, which
was thought to reflect the fibrosis of the tumor. Since
the pre- and post-treatment T2-weighted MRIs were
not the same, imaging at pre-treatment was with fat-
suppression whereas imaging at post-treatment was
without fat-suppression, comparative studies with suf-
ficient numbers of GCTB patients treated with denosu-
mab are needed to test this opinion.
Although we did not perform a biopsy for the femoral
lesions and did not diagnose them pathologically, the
clinical course of the femoral lesions was compatible to
that of the GCTB; the radiological reaction to denosu-
mab treatment was the same as that of the tibial tumor.
Because multicentric GCTB is an extremely rare entity
[17] and the femoral lesions in the present case were
much smaller than the proximal tibial tumor, we diag-
nosed the femoral lesions as skip bone metastases from
the primary tibial GCTB. The long-term prognosis of
GCTB treated only with denosumab (without surgical
treatment) is not yet known, and thus femoral lesions
should be carefully monitored.
In conclusion, we have reported a case of GCTB of the
tibia with skip bone metastases to the ipsilateral femur,
successfully treated with denosumab administration fol-
lowed by surgical treatment. Based on the results of our
comparative radiological and pathological analysis of the
pre-/post-treatment tumor, we found that plain radio-
graphs and 18F-FDG PET/CT are useful tools for clinical
evaluations of the efficacy of denosumab treatment for
GCTB. The present study is preliminary, investigating only
one patient; this is a major limitation. Further radiological
and pathological investigations using larger numbers of
GCTB patients treated with denosumab are necessary.
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